NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Luxna Biotech Co., Ltd.

Luxna Biotech Co., Ltd.

Private
SuitaHealthcare & Life Scienceshttps://luxnabiotech.co.jp/

Last Round

Series C

Extension

Aug 7, 2025

Total Funding Raised

$12.43M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Luxna Biotech Co., Ltd. is a biotechnology company that develops oligonucleotide therapeutics based on modified nucleic acid technology licensed from Osaka University.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Hardware Sales

AI Layer

Non-AI

Keywords

BNAbridging nucleic acidoligonucleotide therapeuticsmodified nucleic acidsoligo synthesisoligonucleotide synthesisphosphoramiditesnucleic acid therapeuticscustom synthesisdrug discovery platformnucleic acid chemistrychemistry manufacturing and controlsCMC supportbiotech supply chain

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Luxna Biotech Co., Ltd. Comparables

Compare Luxna Biotech Co., Ltd. with similar companies based on industry and business-model similarity.

Luxna Biotech Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SynGenis
78%
ChemGenes Corporation
76%
Hongene Biotechnology
76%

Luxna Biotech Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionAug 7, 2025
Series CSep 6, 2024
DebtDec 16, 2021
Series AFeb 10, 2020
DebtNov 1, 2019
Seed
Mar 1, 2018

Key People

Founding team and executive leadership

佐藤秀昭Hideaki Sato

President CEO

Executive Team

Luxna Biotech Co., Ltd. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors increased 156% MoM, reaching 4.3K.

  • Mar 16, 2026

    Partnered with Inabata to expand GuNA amidite supply.

Luxna Biotech Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Luxna Biotech Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Luxna Biotech Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSuita
Employee Range9
Year Founded2017
Last FundingAug 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.